ARENTFOX SCHIFF LLP for ORGANOGENESIS INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Defense DEF
Federal research and development funding regarding regenerative medicine products
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN RENBERG | — |
| OLIVER SPURGEON III New | Legislative Correspondent, Rep. Hank Johnson (2009-2015); Staff Assistant, Rep. Hank Johnson (2007-2009) |
Medicare/Medicaid MMM
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System proposed regulations regarding reimbursement for chronic wound healing product
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN RENBERG | — |
Taxation/Internal Revenue Code TAX
Medical device excise tax H.R.2207 and S.692 (Protect Medical Innovation Act of 2019), all provisions H.R. 1865 (Further Consolidated Appropriations Act, 2020), Division N, Title I, Section 501, regarding medical device excise tax
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
| DAN RENBERG | — |
| OLIVER SPURGEON III New | Legislative Correspondent, Rep. Hank Johnson (2009-2015); Staff Assistant, Rep. Hank Johnson (2007-2009) |
Health Issues HCR
Food and Drug Administration policy on chronic wound healing products
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN RENBERG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.